Tamoxifen—the oldest and the most prescribed drug in breast cancer hormonal therapy—blocks estradiol from binding to the malignant cells and inhibits the growth of estrogen receptor-positive breast cancer cells. Here, ESR1 is linked to breast carcinoma.